Tide Point Capital Management LP Has Decreased Targa Res (TRGP) Position; Infinity Pharmaceuticals (INFI) Shorts Raised By 177.96%

December 8, 2017 - By Clifton Ray

Infinity Pharmaceuticals Incorporated (NASDAQ:INFI) had an increase of 177.96% in short interest. INFI’s SI was 2.07M shares in December as released by FINRA. Its up 177.96% from 745,000 shares previously. With 1.83 million avg volume, 1 days are for Infinity Pharmaceuticals Incorporated (NASDAQ:INFI)’s short sellers to cover INFI’s short positions. The SI to Infinity Pharmaceuticals Incorporated’s float is 5.25%. The stock increased 0.51% or $0.01 during the last trading session, reaching $1.99. About 1.83 million shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since December 8, 2016 and is downtrending. It has underperformed by 77.66% the S&P500.

Tide Point Capital Management Lp decreased Targa Res Corp (TRGP) stake by 74.85% reported in 2017Q2 SEC filing. Tide Point Capital Management Lp sold 312,758 shares as Targa Res Corp (TRGP)’s stock declined 13.24%. The Tide Point Capital Management Lp holds 105,108 shares with $4.75M value, down from 417,866 last quarter. Targa Res Corp now has $9.78 billion valuation. The stock increased 0.78% or $0.35 during the last trading session, reaching $45.36. About 1.73M shares traded or 0.49% up from the average. Targa Resources Corp. (NYSE:TRGP) has risen 18.42% since December 8, 2016 and is uptrending. It has outperformed by 1.72% the S&P500.

Analysts await Targa Resources Corp. (NYSE:TRGP) to report earnings on February, 16. After $-0.15 actual earnings per share reported by Targa Resources Corp. for the previous quarter, Wall Street now forecasts -93.33% EPS growth.

Tide Point Capital Management Lp increased Silver Run Acquisition stake by 810,124 shares to 2.81 million valued at $30.02M in 2017Q2. It also upped Norwegian Cruise Line Hldgs (NASDAQ:NCLH) stake by 52,365 shares and now owns 425,786 shares. Methanex Corp (Put) (NASDAQ:MEOH) was raised too.

Among 19 analysts covering Targa Resources (NYSE:TRGP), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Targa Resources had 74 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Wunderlich on Friday, February 26 with “Hold”. The rating was upgraded by Stifel Nicolaus on Thursday, August 4 to “Buy”. Credit Suisse maintained the shares of TRGP in report on Thursday, May 25 with “Hold” rating. Stifel Nicolaus maintained the shares of TRGP in report on Monday, July 17 with “Buy” rating. The rating was upgraded by Barclays Capital to “Overweight” on Tuesday, September 27. The rating was maintained by Stifel Nicolaus on Monday, August 22 with “Buy”. The stock of Targa Resources Corp. (NYSE:TRGP) has “Buy” rating given on Thursday, January 14 by Jefferies. Deutsche Bank maintained the shares of TRGP in report on Thursday, March 30 with “Buy” rating. The stock of Targa Resources Corp. (NYSE:TRGP) has “Equal Weight” rating given on Monday, May 2 by Barclays Capital. Capital One upgraded Targa Resources Corp. (NYSE:TRGP) on Monday, May 2 to “Overweight” rating.

Investors sentiment decreased to 1.56 in 2017 Q2. Its down 0.05, from 1.61 in 2017Q1. It worsened, as 58 investors sold TRGP shares while 78 reduced holdings. 45 funds opened positions while 167 raised stakes. 182.63 million shares or 11.02% more from 164.50 million shares in 2017Q1 were reported. Salem Invest Counselors Incorporated accumulated 1,855 shares or 0.01% of the stock. Parkwood Ltd reported 35,140 shares. Soros Fund Mngmt owns 320,100 shares. Private Cap Advsrs stated it has 0.29% of its portfolio in Targa Resources Corp. (NYSE:TRGP). British Columbia Mgmt holds 62,859 shares or 0.02% of its portfolio. Nordea Invest Management invested in 5,493 shares. Citigroup holds 72,493 shares or 0% of its portfolio. Advisors Capital Mngmt Llc reported 0.71% of its portfolio in Targa Resources Corp. (NYSE:TRGP). Alabama-based Oakworth Inc has invested 0% in Targa Resources Corp. (NYSE:TRGP). 44,215 are owned by Clinton Group Inc Inc. Andra Ap stated it has 46,500 shares. Nelson Van Denburg And Campbell Wealth Mgmt Grp Ltd reported 0% of its portfolio in Targa Resources Corp. (NYSE:TRGP). Goldman Sachs Gp reported 13.54M shares stake. Whetstone Advisors Ltd Liability Com accumulated 77,900 shares or 1.92% of the stock. Cibc Asset Mngmt Inc invested in 0% or 6,369 shares.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $100.92 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Wednesday, June 15 report. JMP Securities maintained the shares of INFI in report on Wednesday, March 9 with “Market Outperform” rating. Wedbush maintained the stock with “Neutral” rating in Thursday, February 25 report. The firm has “Sector Perform” rating given on Wednesday, June 15 by RBC Capital Markets. The rating was upgraded by Wells Fargo on Thursday, October 12 to “Outperform”. William Blair downgraded the stock to “Market Perform” rating in Wednesday, June 15 report. Wedbush upgraded the stock to “Neutral” rating in Tuesday, June 14 report. The company was downgraded on Wednesday, June 15 by Jefferies. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Overweight” rating given on Monday, September 21 by Morgan Stanley. The stock has “Market Perform” rating by Wells Fargo on Wednesday, June 15.

Investors sentiment decreased to 0.63 in 2017 Q2. Its down 0.11, from 0.74 in 2017Q1. It is negative, as 20 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 15 funds opened positions while 12 raised stakes. 33.31 million shares or 13.10% less from 38.33 million shares in 2017Q1 were reported. Orbimed Advisors Limited Liability Corporation owns 3.25M shares. Morgan Stanley owns 106,512 shares. Royal Bancorp Of Canada holds 1,500 shares or 0% of its portfolio. The Massachusetts-based State Street Corp has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Deutsche Comml Bank Ag owns 219,196 shares or 0% of their US portfolio. Barclays Public Limited has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 34,357 shares. Moreover, Price T Rowe Associate Md has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 267,460 shares. Qs Llc reported 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Hall Laurie J Trustee invested in 0% or 470 shares. Texas-based Dimensional Fund Advisors L P has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Public Employees Retirement Association Of Colorado has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Numeric Invsts Ltd Liability Corp has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Panagora Asset Incorporated holds 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) or 4,391 shares. 625,865 were accumulated by Connor Clark Lunn Investment Ltd. Bnp Paribas Arbitrage invested in 0% or 4,056 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com